

495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538

Supplementary Tables

ST1. Exposure and Outcome Variables During the Study Period

	1992-2000	2001-2010	2011-2014	
N	92	87	95	
PSA testing	49 (53.2%)	43 (49.4%)	56 (59.0%)	0.43
Low-risk	21 (22.8%)	18 (20.7%)	17 (17.9%)	0.42
Intermediate-risk	44 (47.8%)	38 (43.7%)	37 (39.0%)	
High-risk	27 (29.4%)	31 (35.6%)	41 (43.2%)	

539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580

ST2A. Alternative Multivariable Model for PSA Testing

<b>Variable</b>	<b>Odds Ratio (95% CI)</b>	<b>P-value</b>
Age (per 1 year)	0.80 (0.73-0.89)	<0.001
Black race	0.63 (0.33-1.18)	0.15
Diagnosis after 2004	1.16 (0.70-1.92)	0.55

ST2B. Alternative Multivariable Model for High-Risk Cancer

<b>Variable</b>	<b>Odds Ratio (95% CI)</b>	<b>P-value</b>
Age (per 1 year)	1.05 (0.95-1.15)	0.33
Black race	1.94 (1.02-3.72)	0.045
Diagnosis after 2004	1.70 (0.99-2.92)	0.055
No PSA testing	3.36 (1.94-5.81)	<0.001

581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626

ST3. Reason for Initial PSA Test in the Previously Untested Population

	<b>N</b>	<b>% Total</b>	<b>% Determined</b>
Symptoms (LUTS, hematuria)	17	31.5%	56.7%
Abnormal DRE	9	16.7%	30.0%
Discontinued PSA testing for period	4	7.4%	13.3%
Cannot be determined	24	44.4%	--

627  
628  
629  
  
630  
631  
632  
633  
634

ST4. Clinical Characteristics of Intermediate- or High-Risk Cancer in the Tested Population

	<b>N</b>	<b>%</b>
Previous negative biopsy	41	40.2%
Rapid PSA increase	26	25.5%
Low PSA-production	16	15.7%
None of the above	19	18.6%